PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.76%
Cash & equivalents declining -19.76% while TRAW's grows 306.66%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-19.76%
Below half of TRAW's 306.66%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.43%
Other current assets growth 50-75% of TRAW's -89.80%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-20.12%
Below half of TRAW's 252.51%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.37%
Below half TRAW's -29.17%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.42%
Below half of TRAW's -23.33%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Below half of TRAW's 250.59%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.57%
Less than half of TRAW's -15.43%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRAW's 23.13%. David Dodd sees fewer expansions in other current obligations.
-17.63%
Above 1.5x TRAW's -5.46%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.63%
Above 1.5x TRAW's -7.76%. Michael Burry sees a potential leverage warning sign.
0.13%
Less than half of TRAW's 338.66%. David Dodd sees fewer share issuances vs. competitor.
-2.90%
≥ 1.5x TRAW's -0.95%. David Dodd sees higher yoy retained profits than competitor.
-5.63%
Less than half of TRAW's -145.45%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
Below half TRAW's 306.55%. Michael Burry sees potential underperformance in building shareholder capital.
-19.74%
Below half TRAW's 250.59%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.76%
Less than half of TRAW's -306.66%. David Dodd sees better deleveraging or stronger cash buildup than competitor.